Spinal Cord Injury Pain presents the basis for preclinical and clinical investigations, along with strategies for new approaches in the treatment of central neuropathic pain. Contributors from the private sector and academia provide a comprehensive review of state-of-the-art research in this challenging space. Topics include Epidemiology of Chronic Pain Following SCI, experimental models and mechanisms of chronic pain in SCI, and new targets and technologies. This book serves as a resource for continued translational research that will result in novel approaches and treatments that improve function and quality of life for individuals with CNP/SCI.
Despite a better understanding of the complexity of mechanisms of CNP/SCI, improved medical and surgical management of SCI, and the subsequent acceleration of the identification of new targets and the development of novel analgesics, there is still a great unmet clinical need in the area of CNP following SCI. Hence, this book is a welcomed addition to current research and developments.
Hulsebosch, Claire E.: - Claire E. Hulsebosch, Ph.D. is Professor, Department of Neurobiology and Anatomy, McGovern Medical School, The University of Texas Health Science Center at Houston. She pioneered the concept of nerve cell process reorganization and the formation of new nerve connections (synaptogenesis) in the spinal cord after injury, which formed the basis for the subsequent hypotheses involving spinal cord reorganization resulting in central neuropathic pain. She has numerous publications that demonstrate the ability of nerve cells to reorganize after spinal cord injury. In addition, she has several publications examining the ability of nerve fibers to reorganize after brain injury and stroke. Currently, Dr. Hulsebosch is part of the scientific advisory board for both the Neurological Recovery Network and the North American Clinical Trials Network, which are actively involved in advancing clinical trials in spinal cord injury. She serves as scientific advisor to the National Institute of Health for Neuroscience Initiatives, on study section for National Institute of Neurological Diseases and Stroke, on the Craig Neilsen Foundation, the Christopher and Dana Reeves Foundation, the New Jersey Commission for Spinal Cord Injury Research, The Kentucky Initiative for Brain and Spinal Cord Injury Research, The New York Commission for Spinal Cord injury Research and a variety of editorial and review boards for scientific journals. She was a founder and served as Director of Mission Connect, a multi-institutional research group whose mission is to advance research for recovery after brain and spinal cord injury, from 2005 to 2008.
Sang, Christine N.: - Christine Sang, MD, MPH is Associate Professor of Anaesthesia at Harvard Medical School. Dr. Sang served as Associate Medical Director of the Pain Research Clinic at the NIH, Director of the Clinical Trials Program at the Massachusetts General Hospital Pain Center, and is currently the Director of the Translational Pain Research Program at the Brigham and Women's Hospital (BWH). She has served on several committees including the American Pain Society (as director-at-large), American Society of Anesthesiologists (as a member of the chronic pain analgesic guidelines committee), American College of Occupational and Environmental Medicine (as a member of the chronic pain practice guidelines committee), the National Spinal Cord Injury Association/United Spinal Association (as founding chairman of its Medical and Scientific Advisory Committee), North American Clinical Trial Network Neurological Outcomes Assessment Task Force, the Rick Hansen Institute (as director), the Healthcare Institute for National Renewal and Innovation (director), and several local advisory committees including the NIH-funded Harvard University Catalyst, the BWH Clinical Investigation Advisory Committee, the BWH Translational Accelerator Advisory Committee, and the BWH Research Management Task Force. Dr. Sang has specific expertise in the development of innovative clinical trial strategies to accelerate the clinical development of novel analgesics. These include new clinical trial methodologies (in Phase 1a/First-in-Human through to Phase 2a clinical trials) and the discovery of potential clinical biomarkers to to target selective mechanisms of pain by optimizing efficient designs, endpoints (including biomarkers), and execution.
